MEK Inhibitor PD-0325901 Trial in Adolescents and Adults With NF1

PHASE2CompletedINTERVENTIONAL
Enrollment

19

Participants

Timeline

Start Date

June 30, 2014

Primary Completion Date

August 9, 2017

Study Completion Date

August 1, 2018

Conditions
Neurofibromatosis Type 1 and Growing or Symptomatic, Inoperable PN
Interventions
DRUG

PD-0325901

Trial Locations (11)

10016

New York University Medical Center, New York

19096

Children's Hospital of Philadelphia, Philadelphia

20010

Children's National Medical Center, Washington D.C.

20892

National Cancer Institute (NCI), Bethesda

45229

Cincinnati Children's Hospital Medical Center, Cincinnati

46202

Indiana Unversity, Indianapolis

60637

University of Chicago, Chicago

63110

Washington University - St. Louis, St Louis

84132

University of Utah, Salt Lake City

90027

Children's Hospital Los Angeles, Los Angeles

02115

Children's Hospital Boston, Boston

All Listed Sponsors
lead

University of Alabama at Birmingham

OTHER

NCT02096471 - MEK Inhibitor PD-0325901 Trial in Adolescents and Adults With NF1 | Biotech Hunter | Biotech Hunter